Related Experiment Video

Updated: Jun 5, 2026

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells
09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Engineering a waste management enzyme to overcome cancer resistance to apoptosis: adding DNase1 to the anti-cancer

K Rosner1, M F Kasprzak, A C J Horenstein

  • 1Laboratory for Molecular Dermatology, Program in Molecular Biology and Genetics, Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, USA. krosner@med.wayne.edu

Cancer Gene Therapy
|January 15, 2011
PubMed

Insights

Researchers engineered a novel Deoxyribonuclease-1 (DNase1) to overcome cancer treatment resistance. This modified enzyme effectively triggers apoptosis in resistant cancer cells, offering a promising new therapeutic strategy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • Cancer treatment faces challenges due to resistance to conventional therapies, immunotherapy, and gene therapy.
  • Existing treatments aiming to activate cancer cell death pathways are often circumvented by cancer defense mechanisms.
  • Apoptotic signaling cascades can be disrupted by cancer cells, hindering programmed cell death induction.

Purpose of the Study:

  • To develop a novel therapeutic approach for triggering apoptosis in cancer cells independent of the native apoptotic signaling cascade.
  • To engineer a modified Deoxyribonuclease-1 (DNase1) enzyme capable of inducing apoptosis in apoptosis-resistant cancer cells.
  • To evaluate the efficacy of engineered DNase1 in reducing viability and inducing apoptosis in human melanoma cells.

Main Methods:

  • Engineered Deoxyribonuclease-1 (DNase1) by deleting its signal peptide, adding a nuclear localization signal, and mutating its actin-binding site.
  • Conducted apoptosis studies and colony-forming assays in apoptosis-resistant Mel-Juso human melanoma cells.
  • Utilized Laser scanning cytometry for high-efficiency quantification of apoptosis induction.

Main Results:

  • Modified DNase1 significantly reduced cancer cell viability by 77% compared to controls.
  • Induced characteristic features of cellular apoptosis, including DNA fragmentation and Terminal Transferase dUTP Nick-End Labeling-positive cells.
  • Demonstrated high-killing efficiency, ranging from 70-100%, in apoptosis-resistant melanoma cells.

Conclusions:

  • Engineered DNase1 effectively eliminates apoptosis-resistant cancer cells by inducing programmed cell death.
  • This modified DNase1 represents a potential platform for developing new cancer therapies targeting various cancer types.
  • The novel approach bypasses the compromised apoptotic signaling cascade, offering a unique therapeutic strategy.

More Related Videos

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen19:44

Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen

Published on: May 30, 2012

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...